Evidence map›Paper›PMID 37483876›Full record

ArticleNuclear medicine and molecular imaging2023

Evaluation of an Integrin α

Shuichi Hiroyama, Keiko Matsunaga, Miwa Ito, Hitoshi Iimori, Ippei Morita, Jun Nakamura, Eku Shimosegawa, Kohji Abe

Open access · greenAbstract read
In one paragraph

Article in Nuclear medicine and molecular imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Shuichi HiroyamaBiomarker R&D Department, Shionogi & Co., Ltd., 3-1-1 Futaba-Cho, Toyonaka, Osaka 561-0825 Japan.
Keiko MatsunagaDepartment of Molecular Imaging in Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.
Miwa ItoBiomarker R&D Department, Shionogi & Co., Ltd., 3-1-1 Futaba-Cho, Toyonaka, Osaka 561-0825 Japan.
Hitoshi IimoriLaboratory for Advanced Medicine Research, Shionogi & Co., Ltd., Osaka, Japan.
Ippei MoritaLaboratory for Advanced Medicine Research, Shionogi & Co., Ltd., Osaka, Japan.
Jun NakamuraLaboratory for Advanced Medicine Research, Shionogi & Co., Ltd., Osaka, Japan.
Eku ShimosegawaDepartment of Molecular Imaging in Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.
Kohji AbeBiomarker R&D Department, Shionogi & Co., Ltd., 3-1-1 Futaba-Cho, Toyonaka, Osaka 561-0825 Japan.
Shionogi (Japan) · JPFutaba (Japan) · JPThe University of Osaka · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Integrin α Methods: NASH model rats were produced by feeding a choline-deficient, low-methionine, high-fat diet for 8 weeks. PET/computerized tomography imaging and quantification of integrin α Results: Integrin α Conclusion: This study suggests that [

Indexed as

Arginine-glycine-aspartic (RGD)IntegrinNonalcoholic steatohepatitis (NASH)Positron emission tomography (PET)Small interfering RNA (siRNA)

Identifiers

PMID37483876
PMCPMC10359219
OpenAlexW4323360252

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.